Skip to main content

Table 1 Sensitivity of B lymphoid cell lines to IQS019

From: Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

Cell lines

B lymphoid subtypes

TP53 statusa

IQS019 cytotoxic effect (referred to untreated cells)

1 μM, 48 h

5 μM, 48 h

DOHH-2

FL

wt

26%

100%

WSU-NHL

FL

del/mut

6%

80%

WSU-FSCCL

FL

wt

26%

77%

SC-1

FL

del/mut

4%

43%

JEKO-1

MCL

del/mut

21%

75%

MAVER-1

MCL

del/mut

15%

70%

UPN-1

MCL

del/mut

14%

66%

HBL-2

MCL

del/mut

12%

64%

MINO

MCL

del/mut

19%

64%

GRANTA-519

MCL

wt

26%

63%

Z-138

MCL

wt

18%

62%

JVM-2

MCL

wt

16%

58%

REC-1

MCL

wt

12%

48%

MEC-2

CLL

del/mut

12%

51%

JVM-13

CLL

wt

7%

46%

MEC-1

CLL

wt

9%

33%

SUDHL-16

GCB-DLBCL

del/mut

15%

47%

OCI-LY8

GCB-DLBCL

del/mut

2%

29%

SUDHL-8

GCB-DLBCL

del/mut

15%

32%

OCI-LY10

ABC-DLBCL

wt

3%

47%

U-2932

ABC-DLBCL

del/mut

15%

51%

  1. a17p13 deletion was assessed by fluorescence in situ hybridization and TP53 mutational status was analyzed by direct sequencing
  2. Abbreviations: FL follicular lymphoma MCL mantle cell lymphoma, CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma